Loading…
Intellia Therapeutics, Inc. is projected to rise to $12.52 by 2027, a +17% move from its current price of $10.68. NTLA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $10.30 | $10.69 | $11.09 | +0.07% |
| Aug 3 | $10.15 | $10.70 | $11.27 | +0.15% |
| Aug 4 | $10.04 | $10.70 | $11.41 | +0.22% |
| Aug 5 | $9.95 | $10.71 | $11.53 | +0.29% |
| Aug 6 | $9.87 | $10.72 | $11.64 | +0.37% |
| Aug 7 | $9.80 | $10.73 | $11.74 | +0.44% |
| Aug 8 | $9.74 | $10.73 | $11.83 | +0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.74 | $10.73 | $11.83 | +0.51% |
| Week 2 | $9.40 | $10.79 | $12.38 | +1.03% |
| Week 3 | $9.16 | $10.84 | $12.83 | +1.54% |
| Week 4 | $8.98 | $10.90 | $13.24 | +2.06% |
| Week 5 | $8.82 | $10.96 | $13.62 | +2.59% |
| Week 6 | $8.68 | $11.01 | $13.97 | +3.11% |
| Week 7 | $8.56 | $11.07 | $14.31 | +3.64% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
The company offers a modular platform to advance in vivo and ex vivo therapies for diseases. Its in vivo product candidates include NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema.
Intellia has license and collaboration agreements with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd.
for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc.
The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Intellia Therapeutics, Inc. (NTLA) is a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
As of now, the stock trades with current price $10.92 and market cap $1.53B, ranking 2108 by market capitalization. The asset sits in the Healthcare category.
The long-run forecast shows a path with multiple years indicating upside potential, including a 2026 average price of $10.92 and a 2050 average price of $45.51, with a max forecast of $103.65 in 2050.
A major floor 44.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.1% away) — a key level to hold.
The nearest ceiling, 67.0% above — a clean break opens room to run.
A major ceiling 89.5% above — clearing it would confirm fresh momentum.
Key NTLA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NTLA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.83 | Sell | $10.88 | Sell |
| MA 10 | $10.95 | Sell | $11.27 | Sell |
| MA 20 | $12.69 | Sell | $12.20 | Sell |
| MA 50 | $13.68 | Sell | $13.23 | Sell |
| MA 100 | $13.64 | Sell | $13.38 | Sell |
| MA 200 | $13.08 | Sell | $13.26 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.88 | Neutral |
| Stoch RSI (14) | 40.51 | Neutral |
| CCI (20) | -68.47 | Neutral |
| Williams %R (14) | -99.62 | Info |
| MACD (12,26,9) | -0.15 | Sell |
| ROC (12) | -18.10 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 0.38 | Buy |
| TRIX (15) | -0.98 | Sell |
| Awesome (5,34) | -3.11 | Sell |
| Ultimate (7,14,28) | 31.82 | Neutral |
| Momentum (10) | -0.69 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 10.83 | Sell |
| ADX (14) | 29.91 | Sell |
| ATR (14) | 0.44 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 30.
SMA50 is $14.15 and SMA200 is $13.58, placing near-term momentum around the moving averages. The stock shows support at $10.92 and resistance at $17.84, defining a clear trading range in the near term.
The 30-day range spans from $8.15 to $14.63, indicating volatility within a broad band and a price that has recently traded near the stated support level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.21 | $10.68 | $14.54 | 0% | Neutral | |
| $9.67 | $12.52 | $17.32 | +17% | Neutral | |
| $9.96 | $13.41 | $19.46 | +26% | Bullish | |
| $9.08 | $12.63 | $19.02 | +18% | Neutral | |
| $9.07 | $12.99 | $20.18 | +22% | Bullish | |
| $9.61 | $14.14 | $22.56 | +32% | Bullish | |
| $11.04 | $16.66 | $27.23 | +56% | Bullish | |
| $13.26 | $20.50 | $34.22 | +92% | Bullish | |
| $12.59 | $19.92 | $33.92 | +86% | Bullish | |
| $12.09 | $19.54 | $33.89 | +83% | Bullish | |
| $16.84 | $30.12 | $56.35 | +182% | Bullish | |
| $20.99 | $45.10 | $94.04 | +322% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $9.21 | $10.68 | $12.98 | +0.00% |
| September 2026 | $9.36 | $11.19 | $13.83 | +4.73% |
| October 2026 | $9.46 | $11.41 | $14.31 | +2.05% |
| November 2026 | $9.18 | $11.15 | $14.14 | -2.30% |
| December 2026 | $9.27 | $11.35 | $14.54 | +1.75% |
Click any year to see its month-by-month NTLA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The NTLA price prediction for 2026 points to an average of $10.68 (low $9.21, high $14.54) — a potential gain of 0% on today's $10.68. Price action looks broadly range-bound.
In 2027, NTLA is projected to trade between $9.67 and $17.32, averaging $12.52 — a potential gain of +17% from today's $10.68. That is up +17% on the projected 2026 average. A consolidation phase looks the most probable path here.
Intellia Therapeutics, Inc.'s 2028 outlook centres on $13.41, within a $9.96 to $19.46 range. That is up +7% on the projected 2027 average. That marks a +26% change versus current levels. Momentum favours further upside here.
By 2029, NTLA could reach as high as $19.02, with a base case around $12.63 and support toward $9.08 — roughly +18% from $10.68. A consolidation phase looks the most probable path here.
Expect NTLA to range from $9.07 to $20.18 through 2030. The $12.99 average target implies a +22% move from current prices. That is up +3% on the projected 2029 average. Momentum favours further upside here.
The NTLA price prediction for 2031 points to an average of $14.14 (low $9.61, high $22.56) — a potential gain of +32% on today's $10.68. Buyers look set to stay in control over this stretch.
In 2032, NTLA is projected to trade between $11.04 and $27.23, averaging $16.66 — a potential gain of +56% from today's $10.68. That is up +18% on the projected 2031 average. Momentum favours further upside here.
Intellia Therapeutics, Inc.'s 2033 outlook centres on $20.50, within a $13.26 to $34.22 range. That is up +23% on the projected 2032 average. That marks a +92% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, NTLA could reach as high as $33.92, with a base case around $19.92 and support toward $12.59 — roughly +86% from $10.68. Momentum favours further upside here.
Expect NTLA to range from $12.09 to $33.89 through 2035. The $19.54 average target implies a +83% move from current prices. That is -2% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The NTLA price prediction for 2040 points to an average of $30.12 (low $16.84, high $56.35) — a potential gain of +182% on today's $10.68. Momentum favours further upside here.
In 2050, NTLA is projected to trade between $20.99 and $94.04, averaging $45.10 — a potential gain of +322% from today's $10.68. That is up +50% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NTLA today (≈ 93.632959 NTLA) could be worth
$4,222.97
+$3,222.97 (+322%) by 2050 · US Dollar
Based on the average projected NTLA price of $45.1 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NTLAwould be worth at today's price.
$1,000 invested in NTLA on Jul 31, 2025 (≈ 85.91065 NTLA) would be worth
$917.53
-$82.47 (-8.2%) today · 0.92× · US Dollar
Based on a NTLA entry price of $11.64 vs. today's $10.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.73 | $995.34 | -0.5% |
| 1 month ago | $17.24 | $619.49 | -38.1% |
| 3 months ago | $13.26 | $805.43 | -19.5% |
| 6 months ago | $13.06 | $817.76 | -18.2% |
| 1 year ago | $11.64 | $917.53 | -8.2% |
| All time (5.0y) ago | $136.57 | $78.2 | -92.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NTLA forecast.
Our base-case forecast reaches $21.00 around 2040.
Implied market cap at $21.00: $2.93B
The forecasted path for NTLA shows a prolonged multi-year horizon with distinct targets. In 2026 the average price is $10.92, with a min of $9.21 and a max of $15.66 and a neutral sentiment. By 2030 the average price is $12.73, with a min of $8.42 and a max of $20.83 and a 16.6% ROI. The sentiment remains neutral at that horizon.
By 2040 the average price rises to $30.78, with a min of $15.21 and a max of $62.14 and an estimated ROI of 181.8%; the sentiment is bullish. By 2050 the average price reaches $45.51, with a min of $20.48 and a max of $103.65 and an estimated ROI of 316.8%; the sentiment is bullish.
Across 2032–2033–2034–2035 the forecast stays bullish with progressively higher averages and ROI, culminating in a very bullish long-run view for the latter years. The outlook notes high volatility as a risk, with annualized volatility cited at 80%, and emphasizes that these are estimates, not guarantees.
Tap a question to reveal the answer.
Avg $12.73; min $8.42; max $20.83; ROI 16.6%; sentiment NEUTRAL.
Forecasts show a mix of neutral and bullish years, with 2026 at an average of $10.92 (neutral) and longer-horizon years (2032–2050) bullish. These are estimates, not guarantees, and reflect potential upside but also uncertainty.
Yes. The 2050 max forecast is $103.65, which exceeds $50.
Current price is $10.92 and market cap is $1.53B.
The 30-day range is $8.15 to $14.63.
Intellia Therapeutics, Inc. Community Discussion
0Share your Intellia Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.